Various angles of an MRI brain scan.

Why brain mapping changes TMS outcomes

Not all TMS treatment is targeted the same way. Where stimulation is delivered matters, and growing research suggests that using a patient’s individual brain connectivity to identify that target may improve treatment outcomes.

TMS works by delivering magnetic pulses to specific brain areas associated with the condition being treated. Standard TMS typically identifies those areas using scalp measurements or anatomical landmarks. While this approach can be effective, it does not account for individual differences in brain organization and connectivity from person to person.

At Neurotherapeutix, we use fMRI-based brain mapping to examine your individual functional brain organization before treatment begins. This lets our clinical team identify personalized treatment targets based on your brain function, rather than relying solely on standardized locations.

And the difference is more than theoretical. Recent randomized and real-world research shows that individualized, connectivity-based targeting can meaningfully improve TMS treatment response compared with standard targeting methods.

Does brain mapping actually improve TMS outcomes?

Yes. Recent research suggests that individualized, connectivity-based brain mapping can improve TMS outcomes compared with standard scalp-based targeting for treatment-resistant depression.

In a 2026 randomized clinical trial, connectivity-guided patients experienced a 24-point median reduction in depression scores versus 18 points with standard targeting. Real-world research has also reported higher response rates with fMRI guidance.

The reason may come down to a fundamental difference between the two approaches.

Standard targeting identifies treatment locations using standardized methods. Connectivity-guided targeting uses information from your own brain to identify a stimulation site connected to the brain circuit associated with the condition being treated.

Instead of asking, “Where is the target usually located?” personalized targeting allows clinicians to ask, “Where is the relevant target in this patient’s brain?”

The data: fMRI-guided vs. standard TMS targeting

Evidence for personalized targeting has grown considerably.

A systematic review published in The World Journal of Biological Psychiatry evaluated 37 studies involving 1,451 patients who received neuroimaging-personalized TMS. The authors concluded that neuroimaging-personalized TMS may be more effective for depression than standard TMS, while also noting that additional direct comparisons were needed.

Since then, newer head-to-head research has begun providing exactly that type of evidence.

Randomized trial evidence: JAMA Psychiatry, 2026

One of the strongest examples comes from a 2026 randomized clinical trial published in JAMA Psychiatry.

Researchers enrolled 40 adults with moderate-to-severe treatment-resistant major depressive disorder and compared two approaches to accelerated TMS.

Everyone underwent resting-state fMRI (rsfMRI), but only one group used functional connectivity data to determine where stimulation was delivered.

The other group received scalp-based targeting using the Beam F3 method.

One month after treatment, the difference was significant:

  • Connectivity-based targeting: 24-point median improvement on the Montgomery-Åsberg Depression Rating Scale (MADRS)
  • Scalp-based targeting: 18-point median improvement
  • Effect size: 0.8, considered a large effect in the study
  • Number needed to scan: 5, meaning approximately one additional patient benefited from connectivity-based targeting for every five patients scanned

The study also found something particularly relevant to personalized treatment: individualized targets were reproducible within the same patient but differed substantially between patients.

That helps demonstrate why individualized mapping may matter. The optimal functional target doesn’t necessarily fall in the same location for everyone.

You can learn more about the differences between Personalized TMS vs. Standard TMS.

Real-world outcomes with fMRI guidance

1. Randomized trials tell us whether an approach works under carefully controlled conditions.

Real-world clinical data helps answer another important question: Does that advantage still appear in everyday patient care?

A naturalistic study of 195 patients receiving accelerated TMS for depression compared treatment with and without fMRI-guided targeting.

Overall response rates were:

  • 77.4% with fMRI guidance
  • 66.3% without fMRI guidance

Researchers then used propensity-score matching to create more comparable groups.

In that analysis:

  • 77.5% of patients receiving fMRI-guided treatment responded
  • 62.2% of patients receiving non-fMRI-guided treatment responded

That represents a 15.3-percentage-point difference in response rates.

The odds of treatment response were more than twice as high in the fMRI-guided group, and the researchers calculated a number needed to treat of 6.5 for one additional treatment response associated with fMRI guidance.

Because this was an observational study and is currently available as a preprint, it does not carry the same evidentiary weight as the randomized JAMA Psychiatry trial.

But the two studies point in the same direction: individualized functional targeting may improve treatment response compared with standardized targeting.

The Stanford Neuromodulation Therapy (SNT/SAINT) trials

Research from Stanford University provides additional evidence supporting individualized brain connectivity targeting.

A 2022 randomized, sham-controlled trial by Cole and colleagues, published in the American Journal of Psychiatry, evaluated Stanford Neuromodulation Therapy (SNT), an accelerated form of intermittent theta-burst stimulation (iTBS) guided by individualized resting-state fMRI.

Researchers used functional connectivity data to identify stimulation targets in the left dorsolateral prefrontal cortex (DLPFC) based on their relationship with the subgenual anterior cingulate cortex (sgACC), a region involved in mood regulation.

Across the four-week follow-up period:

  • 78.6% of patients receiving active SNT achieved remission at least once, compared with 13.3% in the sham-treatment group.
  • Treatment was delivered over five days using multiple daily stimulation sessions.
  • The results demonstrated the potential of combining accelerated stimulation with individualized connectivity-based targeting.

An earlier open-label study by the same research group also reported promising outcomes, although its uncontrolled design limits direct comparisons with other treatments.

These findings support continued investigation into personalized TMS approaches. However, because SNT combines individualized targeting with an intensive stimulation schedule, its results cannot be attributed to brain mapping alone.

The biological basis of connectivity-based targeting

Why might the location of a TMS target influence treatment response?

A 2012 study by Fox and colleagues, published in Biological Psychiatry, examined the relationship between functional brain connectivity and the effectiveness of TMS targets used for depression.

The researchers found that stimulation sites in the left dorsolateral prefrontal cortex (DLPFC) associated with better antidepressant outcomes tended to have stronger negative functional connectivity, or anticorrelation, with the subgenual anterior cingulate cortex (sgACC).

In simpler terms, the effectiveness of a treatment location may depend partly on how that region communicates with deeper brain networks involved in mood regulation.

This research helped establish an important scientific foundation for connectivity-based targeting: identifying where a brain region is located may be less informative than understanding how it connects with the networks clinicians want to influence.

These findings support the rationale for using functional brain connectivity to guide TMS targeting, although they do not guarantee that any individual patient will respond to treatment.

How functional connectivity mapping informs TMS target selection

A 2023 study by Elbau and colleagues, published in the American Journal of Psychiatry, examined functional connectivity mapping methods used to select TMS targets for depression.

The research explored how individual differences in brain network organization can influence the identification of stimulation sites.

The findings reinforce several important considerations:

  • Brain networks vary between individuals. Two patients with the same diagnosis may have different patterns of functional connectivity.
  • Target location matters. Anatomical landmarks alone may not fully capture the functional networks clinicians aim to influence.
  • Individualized mapping may improve target selection. Functional connectivity data can provide additional information when identifying stimulation sites.

This research adds to the scientific rationale for personalized targeting, but it does not establish that fMRI guidance eliminates treatment nonresponse or guarantees engagement of a specific brain circuit.

For patients, the practical distinction is that computational brain mapping allows treatment planning to consider individual functional brain organization rather than relying solely on standardized anatomical locations.

Why personalized targeting can outperform a one-size-fits-all approach

No two brains are organized exactly alike.

The location and functional connectivity of brain networks vary from person to person. That matters because TMS treatment depends on stimulating a particular area strongly connected to the circuit clinicians are trying to influence.

Traditional TMS targeting methods use standardized approaches to estimate that location.

Those approaches can work well for many patients. But a population-based target cannot fully account for individual differences in functional brain organization.

fMRI-based brain mapping adds that missing layer.

Resting-state fMRI allows us to examine patterns of functional connectivity across your brain. Computational analysis can then identify individualized targets based on how your brain’s regions and networks communicate.

The 2026 randomized trial illustrates this directly. Researchers found that connectivity-based targets were relatively consistent when measured repeatedly within the same person, while the target locations differed significantly from one patient to another.

That means personalization is not simply changing the target for the sake of being different.

It is accounting for measurable differences between individual brains.

That is the foundation of how brain mapping personalizes TMS therapy.

What this means for treatment-resistant cases

This becomes particularly important if you have already tried multiple treatments without enough relief.

You may have taken several medications. You may have spent years in therapy. You may even have completed standard TMS and still be experiencing symptoms.

That does not necessarily mean another treatment approach cannot help.

Treatment resistance is complex, and targeting is only one factor that can influence TMS outcomes. Diagnosis, stimulation protocol, treatment intensity, adherence, individual biology, lifestyle factors, and other clinical considerations also play important roles.

At Neurotherapeutix, our complementary coaching services can help patients address relevant lifestyle and behavioral factors alongside treatment.

But newer research shows that target selection itself can affect treatment response.

For someone considering TMS after previous treatments haven’t provided enough relief, that distinction can matter.

Instead of repeating precisely the same approach, fMRI-based computational brain mapping gives clinicians additional individualized information before treatment begins.

The goal is to give treatment the strongest possible foundation by identifying a target based on your functional brain organization rather than relying solely on a population-based location.

How Neurotherapeutix applies this data to your treatment plan

At Neurotherapeutix, personalization begins before your first TMS treatment.

We use resting-state fMRI to collect information about activity and functional connectivity across your brain. Our team then applies computational analysis to that imaging data to create an individualized functional brain map.

That map helps us identify personalized treatment targets based on your functional brain organization.

Once we identify your treatment target, neuronavigation helps us return accurately to that individualized location during treatment.

We also determine your motor threshold, which helps establish the appropriate stimulation intensity for your TMS protocol. Targeting and dosing are distinct parts of treatment personalization, and we incorporate both into your clinical plan.

This is why brain mapping precision matters.

The goal isn’t simply to do more testing before TMS.

It is to use meaningful information from your own brain to guide decisions that would otherwise rely more heavily on standardized methods.

With fMRI-guided TMS therapy, your imaging data becomes part of how we decide where to deliver treatment.

Complementary coaching services alongside fMRI-guided TMS

At Neurotherapeutix, personalized care extends beyond identifying where to deliver magnetic stimulation.

We also offer complementary coaching services designed to help patients address lifestyle and behavioral factors that may influence brain health, treatment progress, and long-term well-being.

Our approach combines insights from resting-state fMRI and computational brain mapping with ongoing clinical evaluation and guidance from our multidisciplinary team.

Depending on your individual needs, coaching may address:

  • Sleep and circadian rhythms: Building consistent sleep habits and daily routines that support restorative rest.
  • Nutrition and metabolic health: Identifying practical lifestyle changes that support overall physical and brain health.
  • Stress management: Developing strategies to manage stress and strengthen emotional resilience.
  • Daily habits and routines: Establishing sustainable behaviors that support your treatment goals.

Throughout treatment, our team considers your clinical progress, symptoms, and individual circumstances to help develop a personalized plan for continued well-being.

The goal is to support the progress made during fMRI-guided TMS therapy with practical lifestyle strategies you can maintain after treatment ends.

While coaching does not guarantee lasting symptom relief or prevent recurrence, it can provide additional support as part of a comprehensive, individualized treatment approach.

Frequently asked questions

Does brain mapping really change TMS outcomes, or is it marketing?

There is now randomized clinical evidence showing that connectivity-based targeting can improve TMS outcomes compared with scalp-based targeting for treatment-resistant depression.

In the 2026 JAMA Psychiatry trial, patients receiving connectivity-guided accelerated TMS had a median 24-point improvement in MADRS depression scores compared with an 18-point improvement with scalp-based targeting.

The connectivity-guided approach produced a large effect size of 0.8.

Separate real-world data have also found higher response rates among patients receiving fMRI-guided accelerated TMS.

So personalized targeting is more than a theoretical advantage. Measurable clinical evidence supports its potential impact on outcomes.

How much better are outcomes with fMRI-guided targeting?

The exact difference depends on the patient population, treatment protocol, and study.

In the 2026 randomized trial, connectivity-guided treatment produced a 24-point median reduction in MADRS scores compared with 18 points using scalp-based targeting.

In a separate real-world matched analysis, 77.5% of patients receiving fMRI-guided accelerated TMS responded compared with 62.2% receiving treatment without fMRI guidance.

These numbers should not be interpreted as a guarantee of an individual patient’s results, but they demonstrate a clinically meaningful advantage associated with individualized functional targeting in the populations studied.

Is fMRI-guided TMS more effective for everyone?

Individual results vary, and no targeting method can guarantee a particular outcome.

The research shows that fMRI-based connectivity targeting can provide a meaningful advantage by accounting for differences in functional brain organization that standardized targeting does not capture.

That may be particularly relevant for people with treatment-resistant depression or those who did not achieve the results they hoped for with previous treatment.

At Neurotherapeutix, we use your imaging alongside your diagnosis, symptoms, medical history, previous treatment response, and clinical evaluation to determine the approach that fits you.

How does Neurotherapeutix use this data differently than other clinics?

At Neurotherapeutix, fMRI-based computational brain mapping is not an optional add-on to an otherwise standardized process. It underpins how we personalize TMS treatment.

We use functional imaging to examine your individual brain activity and connectivity, computational analysis to identify individualized treatment targets, and neuronavigation to guide stimulation to the planned location during treatment.

We also determine your individual motor threshold to establish stimulation intensity.

Neurotherapeutix is the only clinic in the U.S. offering our patented fMRI-based computational brain mapping approach to guide personalized TMS treatment.

Treatment planning backed by data, not guesswork

The question is no longer simply whether TMS can work.

For patients considering personalized treatment, another important question is: How was the treatment target chosen?

Recent research shows why that question matters.

In a randomized clinical trial, individualized connectivity-based targeting produced greater improvement than scalp-based targeting. Real-world data have also shown higher response rates with fMRI-guided accelerated TMS.

At Neurotherapeutix, those findings reinforce the approach we have built our treatment model around: use the patient’s own functional brain data to make treatment as individualized as possible.

If previous treatments haven’t provided the results you hoped for, a more personalized approach may offer a different path forward.

Request an appointment to learn how fMRI-based computational brain mapping could guide your treatment at Neurotherapeutix.

Would You Like to See a Specialist?

Call us at (917) 388-3090 or click to request a regular or telehealth appointment.

Patient Testimonials

11 Total Reviews

Our Location

Neurotherapeutix
171 East 74th Street, Unit 1-1 New York, NY 10021

QUICK INQUIRY

Are you Looking For
More Information?

Contact us to get an estimate for your medical services requirements. You can fill in the form to specify your medical requirements or you can call us directly.

Contact Form

This field is for validation purposes and should be left unchanged.

Request an Appointment